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Abstract: Topiramate (TPM) is a widely-used drug for the treatment of epilepsy. It is useful 
for several types of partial-onset and generalized-onset seizures, and is therefore considered a 
broad-spectrum agent. It is also effective as a prophylactic against migraine headaches. TPM was 
ﬁ  rst approved for prescription use in 1996. In various countries it is now approved for adjunctive 
and monotherapy of partial-onset seizures and for therapy of generalized tonic-clonic seizures 
of nonfocal origin, for children and adults. For initial monotherapy of new-onset seizures, a 
target dose of 100 mg/day for adults is recommended. Adjunctive use with enzyme-inducing 
drugs and use for refractory seizures requires higher dosages, though the optimum dose for most 
patients does not exceed 400 mg/day. Excretion is primarily renal and TPM is not a signiﬁ  cant 
hepatic enzyme inducer. Although it is usually safe and well-tolerated, adverse effects limit 
use in about 25% of patients. The most salient of these is cognitive dysfunction, especially 
problems with expressive speech and verbal memory. Weight loss, renal stones, paresthesias 
and other central nervous system side effects may occur. Tolerability is improved by low initial 
doses and slow titration to effect.
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Introduction
For almost twenty years between the mid-1970s, when carbamazepine and valproic 
acid were introduced, and 1993, when felbamate was approved, no new antiepilepsy 
drugs were developed for clinical use. In the past 13 years, however, ten new drugs have 
become available. Topiramate is one of the more important of these second-generation 
drugs. In spite of this greatly-expanded range of therapeutic options, about 30% of 
patients remain refractory to medical therapy (Kwan and Brodie 2000), though 5% are 
good candidates for surgery. Optimal use of topiramate and other newer drugs offers 
the possibility of better control for refractory patients, and often provides advantages 
in terms of ease of use and reduction of side effects. This review emphasizes the 
results of randomized controlled clinical trials of TPM and practical considerations 
for maximizing efﬁ  cacy and minimizing adverse effects.
Pharmacology
TPM is a fructose derivative (2,3:4,5-bis-O-(1-methylethylidene)-D-fructopyranose 
sulfamate) (Figure 1). It was synthesized as part of a search for compounds with 
hypoglycemic activity (Maryanoff et al 1987). Although it has no signiﬁ  cant direct 
effects on blood sugar, it was found to be effective in several animal seizure models 
(Shank et al 2000). These include models predictive of efﬁ  cacy against several human 
seizure types: tonic-clonic seizures – the rodent maximal electroshock model (Shank 
et al 1994), complex partial seizures – amygdalar kindling (Wauquier and Zhou 1996), 
and absence seizures – genetic absence epilepsy rats (Rigoulot et al 2003).Neuropsychiatric Disease and Treatment 2007:3(6) 812
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Mechanisms of action
The broad spectrum of activity against various seizure types 
may reﬂ  ect multiple mechanisms of action. Mechanisms 
which have been identiﬁ  ed are:
1.  voltage-gated sodium channel blockade (Coulter et al 
1993; McLean et al 2000)
2.  kainate-type glutamate receptor inhibition (Gryder and 
Rogawski 2003)
3.  reduction of L-type voltage-sensitive calcium currents 
(Zhang et al 2000)
4.  increased frequency of GABA-mediated chloride channel 
opening (White et al 1997; White et al 2000)
5.  carbonic anhydrase inhibition (Dodgson et al 2000)
6.  increased potassium conductance (Herrero et al 2002)
The ﬁ  rst three actions would serve to reduce neuronal 
excitation, the last three would enhance inhibition. It is 
not known which of these proposed mechanisms is most 
important for the antiseizure effects. Neuroprotective effects 
against damage from status epilepticus (Niebauer and 
Gruenthal 1999) and from hypoxia (Koh and Jensen 2001) 
have also been described.
Pharmacokinetics
Linear pharmacokinetics make TPM dosing straightforward. 
It is rapidly and relatively completely (80% bioavailability) 
absorbed after oral dosing (Doose et al 1996). The maximum 
concentration (Cmax) is achieved about 2 hours after an oral 
dose (range 1.4–4.3 hours) (Doose et al 1996); consequently 
this is the time of day at which dose-related adverse effects 
are most likely to occur. About 60% of a dose is excreted 
unchanged by the kidneys; the rest undergoes hepatic 
metabolism to several inactive metabolites (Wu et al 1994; 
Johannessen 1997). With normal liver and kidney func-
tion in monotherapy the elimination half-life (T½) is about 
20–30 hours after single or multiple doses; thus four or ﬁ  ve 
days are required to reach a steady-state serum level with 
constant daily dosing (Doose et al 1996; Perucca 1997). 
Renal insufﬁ  ciency diminishes clearance and prolongs the 
elimination half-life: patients with creatinine clearances 
of 30 mL/min experienced about a twofold increase in 
serum TPM levels (Gisclon et al 1993). Elderly patients 
also require reduced doses because of their expected slightly 
reduced renal function. Clearance in children is faster by 
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Figure 1 Structure of topiramate.Neuropsychiatric Disease and Treatment 2007:3(6) 813
Topiramate
approximately 50% (Rosenfeld et al 1999) and is even faster 
in infants (Glauser 1999); increased doses on a milligram-
per-kilogram basis may therefore be required. Measurement 
of serum levels may be helpful in establishing an appropriate 
daily dose in these special populations.
Drug interactions
Effects of topiramate on other drugs
TPM has little effect upon the pharmacokinetics of other 
drugs because it is not a strong enzyme inducer nor inhibi-
tor (Sachdeo et al 1996; Doose, Brodie et al 2003; Bialer 
et al 2004). However, in three patients with baseline serum 
phenytoin levels of 15 μg/ml or more, phenytoin levels rose 
30%–50% when high doses of TPM (400–800 mg/day) 
were added (Sachdeo, Sachdeo et al 2002). This effect, 
which may be mediated by an inhibitory inﬂ  uence of TPM 
on cytochrome P450 2C19, could cause symptoms of phe-
nytoin toxicity. Theoretically, the same effect could raise 
diazepam levels but this has not been reported. Protein-
binding interactions, such as may occur with phenytoin 
and valproate, are not a problem because TPM is only 
minimally protein bound. Rare cases of hyperammonemic 
encephalopathy have been observed with combination 
topiramate-valproate therapy. This phenomenon does not 
seem to be related to a pharmacokinetic interaction since 
TPM produces little net change in valproate serum levels, 
but it could be related to a shift in valproate metabolic 
pathways toward the 4-ene metabolite in the presence of 
TPM (Hamer et al 2000).
TPM may interfere with the contraceptive effect of 
birth control pills by inducing the metabolism of estrogen. 
In one study, doses of 200 mg/day or more reduced ethinyl 
estradiol levels derived from oral contraceptives by 30% 
(Rosenfeld et al 1997). However, progesterone levels are not 
affected (Doose, Wang et al 2003), and the risk of unwanted 
pregnancy may therefore be lower than with drugs such as 
phenytoin and carbamazepine which induce the metabolism 
of both hormones. Women should be cautioned about the 
possibility of birth control failure. Use of a second or an 
alternate method or of a higher dose of estrogen may be 
considered.
TPM slightly decreases the serum levels of amitryptiline, 
lithium, and risperidone (Bialer et al 2004). Effects on other 
psychoactive agents are unknown. TPM is often used as a 
prophylactic against migraine; it is helpful to know that 
it has no pharmacokinetics effects upon the antimigraine 
agents dihydroergotamine, propranolol, and sumatriptan 
(Bialer et al 2004).
Effects of other drugs upon topiramate
In contrast to the minor effects of TPM on other drugs, 
enzyme-inducing drugs have major inﬂ  uences on the disposi-
tion of TPM. Phenytoin and carbamazepine each double the 
clearance of TPM and therefore reduce TPM serum levels by 
up to 50% (Sachdeo, Sachdeo et al 2002; Neurologics 2006). 
Barbiturates likely have a similar effect but have not been 
studied. Conversely, when one of these drugs is withdrawn 
from a combination regimen, TPM levels will rise and this 
could result in dose-related adverse effects. However, this 
is often offset by the improved tolerability resulting from 
removal of the concomitant drug.
Efﬁ  cacy: partial-onset seizures
Refractory partial-onset seizures: 
adjunctive therapy
As with all antiepilepsy drugs developed within the past 
twenty years, TPM was ﬁ  rst tested in populations of patients 
with refractory partial-onset seizures, as an adjunctive agent. 
These patients are the most numerous in epilepsy treatment 
centers.
The ﬁ  rst trials in the United States enrolled adults tak-
ing one or two concomitant antiepilepsy drugs. Early results 
established excellent efﬁ  cacy at all daily dosages of 200 mg 
or more (Faught et al 1996; Privitera et al 1996). Dosages of 
600–1000 mg/day conferred no additional reductions in seizure 
frequency but caused more adverse effects. The optimum dose 
of 400 mg/day produced a “responder rate” – the percentage 
of patients experiencing at least a 50% reduction in seizure 
number from their baseline – of 41% (Faught et al 1996). 
Additional studies with comparable populations carried out 
in Europe, Korea, and Canada conﬁ  rmed these results and 
established that lower dosages of 200–400 mg/day are effective 
as adjunctive therapy (Ben-Menachem et al 1996; Sharief et al 
1996; Tassinari et al 1996; Korean Topiramate Study Group 
1999; Guberman et al 2002). A clinical trial in children aged 
1–16 years produced a similar result, with a median percent 
reduction from baseline in seizure frequency of 33% compared 
to 11% with adjunctive placebo (Elterman et al 1999).
Open-label studies do not suggest excessive development 
of tolerance to the antiepilepsy effects of TPM with long-
term treatment, with retention rates on drug of 30%–50% 
for 3–4 years, most dropouts being due to adverse effects 
(Abou-Khalil 2000; Lhatoo et al 2000; Bootsma et al 2004). 
However, it is probable that tolerance develops in some 
patients with refractory epilepsy treated with any antiepilepsy 
drug (Loescher and Schmidt 2006).Neuropsychiatric Disease and Treatment 2007:3(6) 814
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Refractory partial-onset seizures: 
monotherapy
Adults with four or more seizures per month despite taking one 
or two drugs were gradually converted to monotherapy with a 
low dose – 100 mg/day – or a very high dose – 1000 mg/day – of 
TPM as the baseline drugs were simultaneously withdrawn 
(Sachdeo et al 1997). Patient safety was addressed by stopping 
rules such as a doubling of baseline seizure frequency or the new 
occurrence of a tonic-clonic seizure. This trial was designed to 
demonstrate TPM efﬁ  cacy as monotherapy, not to establish a 
recommended monotherapy dose or to quantify improvement in 
comparison to previous treatment. The study achieved this goal, 
as signiﬁ  cantly more of the high-dose subjects were converted 
successfully without invocation of a stopping rule (p  0.01).
Partial and generalized new-onset 
seizures: monotherapy
Two clinical trials of TPM monotherapy employed a similar 
design, with children and adults with presumed partial-onset 
seizures being randomized to a lower or to a higher dose. In 
the ﬁ  rst trial (Gilliam et al 2003), 252 patients aged 3 years 
or more took a low dose (50 mg/day for those weighing 50 kg 
or more, 25 mg/day for those weighing 50 kg) or a high 
dose (500 mg/day for weight of 50 kg or more, 200 mg/day 
for weight 50 kg). Doses were adjusted only for weight, not 
for age. Fifty-six percent of subjects were on no antiepilepsy 
drug; the others were already taking one drug (usually phe-
nytoin) which was withdrawn over the ﬁ  rst six weeks. Results 
were inconclusive for time to the ﬁ  rst seizure, but favored the 
high dose (p  0.01) when time to the second seizure was 
added as a covariate. The second trial (Arroyo et al 2005) 
used an identical design except that patients 6 years and older 
were enrolled and the low-dose target was 50 mg/day, the 
high-dose target 400 mg/day. Time to the ﬁ  rst seizure favored 
the high dose, with seizure-free rates of 59% and 76% for 
the low and high doses respectively (p = 0.001).
It is often difﬁ  cult to determine during the initial evalua-
tion of a patient with new-onset seizures whether they are of 
partial or generalized origin. This is especially true if the event 
was a convulsion – a generalized tonic-clonic seizure, which 
could have originated locally or generally. For this reason, 
most new-onset therapeutic trials include a mixture of seizure 
types. This is obviously undesirable but does reﬂ  ect the real-
life clinical situation. Recognizing this difﬁ  culty, investigators 
designed a study allowing for entry of all new-onset seizure 
patients, but with a provision for varying the control drug by 
the physician’s choice (Privitera et al 2003). In this study, 
monotherapy doses of TPM were employed in a three-way 
randomized, blinded comparison to valproate and to carbam-
azepine. A novel feature of this trial was the permission for the 
treating physician to select either valproate or carbamazepine 
as the control agent. It was anticipated that if generalized-
onset seizures were suspected, valproate would be chosen, 
and if partial-onset seizures were suspected, carbamazepine 
would be chosen. This was usually, but not always, the case, 
in part reﬂ  ecting the difﬁ  culty physicians have in making this 
distinction early in the course of the disorder. After this choice, 
patients were randomized to receive TPM 100 mg/day, TPM 
200 mg/day, carbamazepine 600 mg/day, or valproate 1000 
mg/day. All treatments proved equally effective, thus TPM 
100 mg/day was recommended by the authors as the initial 
target dose for patients with new-onset seizures. A word of 
caution is necessary in interpreting new-onset seizure drug 
comparisons: many patients would achieve good control 
regardless of the drug chosen, some would be refractory from 
the outset. The presence of these two categories of patients 
in signiﬁ  cant numbers would tend to reduce the sensitivity of 
the study to detect differences in efﬁ  cacy. Indeed, nearly all 
such comparisons in recent years have shown efﬁ  cacy to be 
equivalent between many pairs of drugs; larger sample sizes 
may be needed to detect any true differences.
In order to address the problem of sample size in new-
onset epilepsy, the recent SANAD (Standard And New 
Antiepileptic Drugs) study in the United Kingdom employed 
a very large number of investigators to enroll 1721 patients 
with partial epilepsy and 716 with generalized or unclas-
siﬁ  able epilepsy (Marson et al 2007a, 2007b). This study 
was randomized but unblinded, and allowed considerable 
dosing ﬂ  exibility. Lamotrigine was found to be the best 
drug for partial epilepsy based on “time to treatment failure” 
but its superiority over carbamazepine, oxcarbazepine, and 
topiramate was entirely due to superior tolerability; there 
were no signiﬁ  cant differences in efﬁ  cacy of seizure control 
among these drugs (Marson et al 2007a). Similarly, in the 
generalized epilepsy study, valproate was deemed superior 
to lamotrigine based on efﬁ  cacy, but its superiority to topira-
mate was based on tolerability; the efﬁ  cacy of valproate and 
topiramate was equivalent (Marson et al 2007b).
Generalized-onset seizures
Generalized tonic-clonic seizures
of nonfocal origin
TPM  is  effective  against  generalized  tonic-clonic  seizures  –                                                
“grand mal” – whether of partial origin (“secondarily 
generalized”) (Faught et al 1996, Privitera et al 1996) or of 
generalized origin (“nonfocal origin”). The latter condition Neuropsychiatric Disease and Treatment 2007:3(6) 815
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was investigated in a double-blind placebo controlled study of 
80 patients aged 3 to 59 years (Biton et al 1999). The median 
baseline seizure frequency was 4.5 per month for the placebo 
group and 5.0 per month for the TPM group: these patients had 
quite severe epilepsy. The median TPM dose achieved during 
the stable dose period was 5 mg/kg/day, a moderate dose. 
The median percent seizure reduction was 57% for adjunc-
tive TPM and 9% for adjunctive placebo (p = 0.019). The 
responder rate (50% or better reduction in seizure frequency) 
was 56% for TPM and 20% for placebo (p = 0.001).
Other primary generalized epilepsies
Primary generalized epilepsies are syndromes producing 
generalized-onset seizures but are otherwise associated with 
little or no neurological dysfunction. They are probably of 
genetic origin and typically appear at ages characteristic for 
each syndrome. Few data concerning the effect of TPM in 
these syndromes are available. Small open-label series sug-
gest efﬁ  cacy in childhood absence epilepsy (Cross 2002) and 
juvenile myoclonic epilepsy (Biton and Bourgeois, 2005, 
Sousa Pda et al 2005). Since juvenile myoclonic epilepsy 
is a common cause of convulsions in teenagers and young 
adults, it is probable that many of the patients in the study of 
generalized tonic-clonic seizures of nonfocal origin (Biton 
et al 1999) had this syndrome.
Secondary generalized epilepsies
This category of the International Classiﬁ  cation of Epilepsies 
and Epilepsy Syndromes includes conditions characterized 
by moderate to severe underlying brain pathology with epi-
lepsy as a prominent symptom. Many of these patients have 
intellectual disabilities or other neurological deﬁ  cits and their 
seizures are often refractory to treatment. The most common 
of these diseases is the Lennox – Gastaut syndrome.
Lennox – Gastaut syndrome: adjunctive 
treatment
A triad of atypical absence seizures, intellectual disabilities, 
and a “slow spike-and-wave” EEG pattern typiﬁ  es this syn-
drome, which usually begins in early childhood. Most patients 
have other seizure types, especially “drop attacks” – a term 
subsuming atonic, axial tonic, and generalized tonic-clonic 
seizures. Valproate is a drug of choice but frequently fails 
to control seizures adequately. Ninety-eight patients aged 
2–42 (mean age 11) were randomized to adjunctive placebo 
or adjunctive TPM; a mean TPM dosage of 5.8 mg/kg/day 
was achieved (Sachdeo et al 1999). Baseline therapy usu-
ally included valproate. Drop attacks were reduced 15%
in the TPM group; they increased 5% in the placebo group 
(p = 0.041). Fifty-two percent of TPM patients vs 38% of 
placebo patients experienced an improvement in seizure 
frequency as judged by parents (p = 0.040).
Other secondary generalized epilepsies
Except for the Lennox – Gastaut syndrome, none of the 
secondary generalized epilepsies have been the subject of 
controlled clinical trials. Most are infrequent or rare.
Infantile spasms (West syndrome)
Infantile spasms (West syndrome) are ominous events; they 
often occur as precursors to the Lennox – Gastaut syndrome 
and are associated with a high rate of intellectual disability in 
later life. The diagnosis is most commonly made during the 
second half of the ﬁ  rst year of life. Several small open-label 
studies have reported improvements in some patients with 
infantile spasms and in the associated hypsarrhythmic EEG 
abnormality with TPM treatment (Glauser et al 1998; Thijs 
et al 2001; Grosso et al 2005; Valencia et al 2005; Hosain 
et al 2006).
Dravet’s syndrome
Dravet’s syndrome is also known as severe myoclonic 
epilepsy of infancy. Four open-label reports, collectively 
including 57 patients, reported good improvement in 31 cases 
(Nieto-Barrera et al 2000; Coppola et al 2002; Mikaeloff et al 
2003; Grosso et al 2005).
Progressive myoclonic epilepsies
Progressive myoclonic epilepsies are syndromes character-
ized by myoclonic and generalized tonic-clonic seizures and 
progressive cerebral dysfunction. Their etiologies are het-
erogeneous. Valproate is usually prescribed for the seizures; 
TPM may be a useful adjunct (Aykutlu et al 2005).
Status epilepticus
TPM has been used effectively in some cases of status 
epilepticus refractory to other agents (Towne et al 2003). 
Since there is no parenteral form, tablets must be crushed 
and administered by nasogastric tubing.
Adverse effects
Serious adverse effects of TPM are rare, but effective use 
requires familiarity with several common mild to moderate 
effects. Adverse effects resulted in discontinuation of TPM 
in 11%–28% of patients during brief adjunctive therapy clini-
cal trials (Reife et al 2000); this is within the higher range of 
discontinuations of most other new antiepilepsy drugs tested Neuropsychiatric Disease and Treatment 2007:3(6) 816
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under similar circumstances (Faught and Limdi 2002). The 
most common reason for discontinuation is the occurrence of 
cognitive problems (Tatum et al 2001; Bootsma et al 2004). 
However, the persistence rate – the percentage of patients 
still taking TPM 36 three years after initiation, is 30%, in the 
higher range of retention for new antiepileptic drugs (Lhatoo 
et al 2000). These data suggest that if patients tolerate TPM 
treatment early in treatment, they have a good chance of 
continuing to have satisfactory results for a long time.
Cognitive effects
Expressive language difﬁ  culty, especially word-ﬁ  nding dif-
ﬁ  culty and mild dysnomia, is common, and may be more 
prevalent in patients with pre-existing dominant hemisphere 
dysfunction (Mula et al 2003). This effect is also seen in 
normal volunteers given topiramate (Meador et al 2005). The 
degree of language dysfunction varies from a minor annoy-
ance to a signiﬁ  cant problem, and may be unnoticed by the 
patient. This effect is rather speciﬁ  c for TPM and is rarely 
seen with other antiepilepsy drugs apart from the setting of 
a generalized cognitive impairment; with TPM it may be the 
only side effect. Verbal memory impairments can be demon-
strated in some patients (Aldenkamp 2000; Aldenkamp et al 
2000; Meador et al 2003), especially to immediate working 
memory (ie, digit span) (Lee et al 2006).
More global cognitive difﬁ  culties may occur. In the early, 
high-dose, rapid titration adjunctive therapy clinical trials 
“thinking abnormal” (a rather nonspeciﬁ  c World Health 
Organization coding term) was reported in 13%–33% and 
“concentration impaired” in 15%–25%; often these were 
in the same patients (Reife et al 2000). These effects are 
clearly dose-related (Shorvon 1996). In a study of lower-
dose adjunctive TPM, 200 mg/day, using a slow titration 
rate of 25–50 mg/day increases weekly, only 5% of patients 
experienced “concentration/attention difﬁ  culty” (Guberman 
et al 2002).
Monotherapy is better tolerated, with reductions in the 
probability of individual cognitive side effects to below 
10% in most series (Sachdeo et al 1996; Gilliam et al 2003; 
Arroyo et al 2005). Cognitive adverse effects of TPM are 
not inevitable. Even at higher doses, many patients are unaf-
fected; group differences are strongly inﬂ  uenced by a subset 
of patients signiﬁ  cantly impaired (Meador et al 2003).
On the other hand, there is one report that low-dose 
monotherapy may cause subjective and objective cognitive 
problems: dose-related decrements in verbal ﬂ  uency and 
working memory (as measured by digit span) displayed a 
clear dose-response relationship to doses of 75, 100, and 
200 mg/day in an open-label monotherapy series of 36 
epilepsy patients (Lee et al 2006). Moreover, these effects 
were present even after one year of treatment, at which time 
44% of the patients had cognitive complaints, though most 
were mild. In this study the 50 mg/day dose did not affect 
cognitive function, and many patients chose to continue the 
higher doses anyway because of good seizure control.
The mechanism of the cognitive side effects is unclear; 
they are often observed independently of changes in level of 
alertness or mood. Functional magnetic resonance imaging 
(fMRI) revealed decreased activation of prefrontal cortex 
in response to a verbal task in normal volunteers who took 
TPM (Jansen et al 2006), but the biochemical mechanism 
is unknown.
Effects on cognition may be subtle and may not be vol-
unteered by the patient: it is necessary to search for them 
by directed questioning, and it is often helpful to interview 
the family.
Weight loss and anorexia
TPM therapy causes an average decrease in body weight of 
4.6%. This is apparently the result of anorexia and weight 
tends to stabilize by 18 months of treatment (Rosenfeld and 
Slater 2002; Ben-Menachem et al 2003). Obese patients may 
lose more. This is often a beneﬁ  t but can limit therapy in 
patients who cannot voluntarily increase their caloric intake 
and in children.
Somnolence and fatigue
Sleepiness occurs early in therapy in 15%–35% of patients 
but usually resolves (Faught et al 1996; Privitera et al 
1996; Tassinari et al 1996). Cognitive effects can occur in 
the absence of sedation. Fatigue (asthenia) was noted in 
13%–16% of child and adult participants in clinical trials 
(Waugh and Goa 2003; Neurologics 2006). Fatigue may 
continue indeﬁ  nitely in some patients.
Carbonic anhydrase inhibition effects
TPM is a weaker carbonic anhydrase inhibitor than acetazol-
amide, but may still produce paresthesias, renal stones, and 
reductions in serum bicarbonate. These effects are related 
to inhibition of carbonic anhydrase isozymes CA II and 
CA IV (Dodgson et al 2000). The most common of these is 
paresthesias. Paresthesias, typically nonpainful tingling in 
the extremities, occur often in monotherapy; for example in 
35%–49% of patients in migraine trials (Neurologics 2006). 
They are usually transient, do not require drug discontinua-
tion, and patients can be reassured that they are harmless.Neuropsychiatric Disease and Treatment 2007:3(6) 817
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Renal stones
Renal stones occur in 1%–2% of patients (Neurologics 2006). 
TPM reduces urinary citrate excretion and thus raises urine 
pH (Sachdeo, Wasserstein et al 2002). There is no clear 
relationship to dose or to duration of therapy. Previous renal 
stones are a relative contraindication to TPM. Increased ﬂ  uid 
intake may be protective. Routine urinalysis is not recom-
mended; symptoms are usually unmistakable.
Metabolic acidemia
Metabolic acidemia is a consequence of lowered serum bicar-
bonate levels, a dose-dependent effect of TPM. An average 
decrease of 5.1 meq/L has been reported in adults (Garris and 
Oles 2005), although the manufacturer states that 32% of adults 
taking 400 mg/day had levels of 20 meq/L or lower (Neurologics 
2006). The practical consequences of this are uncertain. It is 
asymptomatic, but could be signiﬁ  cant in the setting of metabolic 
acidosis from other causes such as diabetes, sepsis, status epilep-
ticus, or the ketogenic diet. Chronic acidemia theoretically could 
have deleterious long-term effects on bone nutriture, though the 
effect of TPM on bone health, if any, remains unknown.
Disorders of mood
Depression is common in epilepsy and affected the same per-
centage of patients taking either TPM or placebo in the ﬁ  rst 
ﬁ  ve clinical trials, about 15% (Shorvon 1996). Depression, 
irritability, or aggressiveness affected 12% of TPM patients 
in one open-label series (Bootsma et al 2004), and 5%–6% 
in another (Kanner et al 2003). Psychiatric side effects were 
more common in patients with previous psychiatric histories 
(Kanner et al 2003).
Psychosis
There are occasional reports of psychosis apparently pre-
cipitated by antiepileptic drugs, and TPM is no exception. 
Paranoia was the major feature in most of the patients in our 
experience; psychotic symptoms resolved quickly with TPM 
discontinuation or dose reduction (Khan et al 1999).
Rash
TPM has a low rash rate in comparison to other antiepilepsy 
drugs. About 4% of patients taking TPM in clinical trials 
developed rashes, not statistically more than placebo (Neu-
rologics 2006). This is lower than the 8%–14% rate seen with 
phenytoin, carbamazepine, or lamotrigine (Faught 1999) and 
it is therefore a good choice for patients who have had rashes 
on other antiepilepsy agents. There is no discernible risk of 
life-threatening skin reactions.
Uncommon systemic effects
Acute secondary angle-closure glaucoma
Acute secondary angle-closure glaucoma occurs rarely 
(Fraunfelder et al 2004). Routine surveillance is unneces-
sary because the symptoms-severe pain, redness, and blurred 
vision – are unlikely to be ignored. This problem begins within 
a few days of drug initiation, at low doses. It resolves quickly 
with TPM discontinuation and does not require surgery.
Hypohidrosis
Hypohidrosis (inappropriately decreased sweating) has been 
reported in a small number of children and could cause 
dangerous hyperthermia (Ben-Zeev et al 2003). This may 
be related to the carbonic anhydrase inhibition (Cerminara 
et al 2006). Parents should be cautioned about this possibility, 
especially in hot climates.
Encephalopathy
Encephalopathy with hyperammonemia has been described 
in a small number of cases in which TPM was used with 
concomitant valproate (Hamer et al 2000; Longin et al 2002; 
Latour et al 2004; Cheung et al 2005). Of, course valproate 
alone can also produce this effect. Nevertheless, TPM plus 
valproate is often a useful combination, especially for patients 
who have gained weight on valproate.
Overdose
TPM has a wide therapeutic margin and serious effects of 
overdose occur rarely (Lofton and Klein-Schwartz 2005). 
Hemodialysis should remove TPM effectively, if necessary, 
since protein binding is low (Schneiderman 1998).
Use in pregnancy
The safety of TPM for use during pregnancy has not been 
established. So far, there are insufﬁ  cient numbers of women 
taking TPM enrolled in the various prospective pregnancy 
registries of antiepilepsy drugs to draw any conclusions. Limb 
and craniofacial anomalies were observed in the offspring 
of rodents and rabbits given high doses during gestation 
(Neurologics 2006). These effects are similar to those seen 
in animals given acetazolamide, although acetozalamide is 
not known to be a human teratogen (Nakatsuka et al 1992). 
This uncertainty should be weighed against the known risk 
of older drugs and the deﬁ  nite risk, to mother and fetus, of 
convulsive seizures during pregnancy.
Patient education
It is not practicable to recite every possible side effect to 
patients before prescribing, but the possibility of somnolence, Neuropsychiatric Disease and Treatment 2007:3(6) 818
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cognitive or speech slowing, and paresthesias should be 
mentioned with the qualiﬁ  cation that they are usually tran-
sient. The 1.5% kidney stone rate should be stated along 
with advice to maintain good hydration, especially in hot 
weather. Advise patients to contact the physician at once 
with symptoms of glaucoma (eye pain, sudden myopia) or 
with a rash. Parents of small children should be advised to 
watch for symptoms of hyperthermia.
Monitoring for side effects
No routine monitoring of hepatic function or hematologic 
parameters is required. A baseline serum bicarbonate and 
repeat measurement at the target dose and after any large dose 
increases may be considered, though the need for correction is 
unclear. Both the patient and the family should be questioned 
about the presence of cognitive or psychiatric adverse effects. 
There is no battery of speciﬁ  c tests for topiramate toxicity 
but special attention should be paid to assessment of verbal 
ﬂ  uency and expressive speech.
Practical use of topiramate
TPM is available as 25, 50, 100, and 200 mg tablets and as 
15 and 25 mg sprinkle capsules. The capsules can be swal-
lowed or opened and sprinkled on food; the contents may 
adhere to the walls of tubing so crushed tablets are preferable 
for administration via feeding tubes. No parenteral form is 
available.
Initial dosing
Tolerability is improved by low initial doses with slow 
titration to the desired target dose in both adults (Biton et al 
2001; Dodson et al 2003) and children (Albsoul-Younes et al 
2004). Early side effects usually subside within a few weeks 
(Majkowski et al 2005). Reduction of the dosage of concomi-
tant antiepilepsy drugs is often effective in reducing central 
nervous system symptoms (Naritoku et al 2005); in one 
open-label study discontinuations dropped from 23% to 14% 
when other drug dosages were lowered (Dodson et al 2003). 
Although the manufacturer recommends a starting dose of 50 
mg/day for adults, it is often a better strategy to begin with 
25 mg/day with increases no faster than 25 mg/week, unless 
there is a need for haste. The ﬁ  rst-week dose should be given 
at bedtime, and if the twice-daily dose is asymmetrical, the 
larger dose should be in the evening. A comparable initial 
dose for children is 0.5 to 1 mg/kg/day, with increases of the 
same amounts at weekly intervals. The monotherapy stud-
ies demonstrated the beginning of a signiﬁ  cant antiseizure 
effect even at 50–100 mg/day (Arroyo et al 2005, Gilliam 
et al 2003), thus patients should have some protection early. 
On the other hand, larger initial doses do not compromise 
safety, only tolerability. If the situation warrants, for example 
with inpatients having active seizures, larger doses such as 
100–200 mg/day may be started. This procedure ordinarily 
should be undertaken in hospital.
Dose targets
For new-onset epilepsy, a target dose of 100 mg/day has 
been suggested (Privitera et al 2003). For adjunctive therapy 
of partial-onset seizures, 200 mg/day was shown to reduce 
seizure frequency almost as well as higher doses in most 
patients (Guberman et al 2002). Above 400 mg/day, there 
was little additional beneﬁ  t among the population of refrac-
tory patients receiving concomitant medications (Faught et al 
1996; Privitera et al 1996).
However, individual patients may have better seizure 
control with doses as high as 1200 mg/day, and increasing 
the dose gradually to complete control or to clinical toxicity 
is reasonable if some beneﬁ  t is noted at lower doses. If no 
beneﬁ  t is seen at 400 mg/day, it is unlikely that signiﬁ  cant 
beneﬁ  t will be seen at higher doses; in that case it makes sense 
to abandon the drug and try something else even if 400 mg is 
well-tolerated. In an open-label trial involving 441 patients 
at 127 sites, primarily in Europe, the average monotherapy 
dose achieved was 125 mg/day (range 25–700) (Guerrini et al 
2005). This trial also enrolled 114 children less than 12 years 
old; the median ﬁ  nal TPM dose reached was 3.3 mg/kg/ day 
(range 1.3–13.0). Another large naturalistic trial in the United 
States assessed adjunctive therapy in adults, mostly with 
enzyme inducing drugs: ﬁ  nal doses were most commonly in 
the 300–350 mg/day range (Dodson et al 2003).
Dosing frequency should be twice daily. In monotherapy 
or in the absence of enzyme-inducing drugs, once-daily dos-
ing may be allowable. In that case, bedtime dosing is most 
likely to ameliorate side effects.
Dosing, as with all antiepilepsy drugs, is best adjusted 
by clinical response rather than by serum level measure-
ments. However, levels are available and can be helpful 
in some circumstances, for example to assess the effect of 
enzyme-inducing drugs on topiramate pharmacokinetics 
or to investigate compliance. Serum levels of 2.5–10.5 
micrograms/milliliter are associated with the antiseizure 
effect (Christensen et al 2003), though some patients will 
beneﬁ  t from higher levels and some will do well with lower 
levels. A withdrawal syndrome has not been described, 
though it is always prudent to withdraw antiepilepsy drugs 
gradually.Neuropsychiatric Disease and Treatment 2007:3(6) 819
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TPM is relatively expensive in comparison to older drugs, 
and cost is a barrier to its use in many countries. Pharma-
coeconomic analyses are locale-speciﬁ  c and not very useful 
worldwide. Eventually, generic preparations may result in 
wider availability.
Summary
Advantages and disadvantages of topiramate are summarized 
in Table 1. TPM is a potent drug effective against most 
seizure types, is remarkably safe, requires little monitoring, 
and displays a relatively favorable pharmacokinetic pro-
ﬁ  le. It is appropriate for initial monotherapy as well as for 
monotherapy or adjunctive therapy in refractory patients. It 
is especially attractive for patients who may also beneﬁ  t from 
its anorectic and antimigraine effects. The major problem 
limiting its use is the frequent occurrence of cognitive adverse 
effects, especially expressive language dysfunction.
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